639 related articles for article (PubMed ID: 15759279)
1. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.
Meriläinen O; Hakkarainen T; Wahlfors T; Pellinen R; Wahlfors J
Int J Oncol; 2005 Jul; 27(1):203-8. PubMed ID: 15942661
[TBL] [Abstract][Full Text] [Related]
3. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
Kong BH; Wang WX; Liu CS; Ma DX; Qu X
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
[TBL] [Abstract][Full Text] [Related]
4. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.
Liu CS; Kong B; Xia HH; Ellem KA; Wei MQ
J Gene Med; 2001; 3(2):145-52. PubMed ID: 11318113
[TBL] [Abstract][Full Text] [Related]
5. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
6. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
7. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.
Dilber MS; Phelan A; Aints A; Mohamed AJ; Elliott G; Smith CI; O'Hare P
Gene Ther; 1999 Jan; 6(1):12-21. PubMed ID: 10341871
[TBL] [Abstract][Full Text] [Related]
8. VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection.
Sheridan PJ; Lawrie A; Crossman DC; Holt CM; Newman CM
J Gene Med; 2005 Mar; 7(3):375-85. PubMed ID: 15543525
[TBL] [Abstract][Full Text] [Related]
9. Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase.
Roy V; Qiao J; de Campos-Lima P; Caruso M
Gene Ther; 2005 Jan; 12(2):169-76. PubMed ID: 15483667
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
Kong B; Wang W; Liu C; Song L; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Wang B; Wei MQ; Yang Q
In Vivo; 2003; 17(2):153-6. PubMed ID: 12792977
[TBL] [Abstract][Full Text] [Related]
13. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
[TBL] [Abstract][Full Text] [Related]
14. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
17. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
Zavaglia D; Lin EH; Guidetti M; Pluquet O; Hainaut P; Favrot MC; Coll JL
J Gene Med; 2005 Jul; 7(7):936-44. PubMed ID: 15754307
[TBL] [Abstract][Full Text] [Related]
18. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.
Rautsi O; Lehmusvaara S; Ketola A; Määttä AM; Wahlfors J; Pellinen R
Cancer Gene Ther; 2008 May; 15(5):303-14. PubMed ID: 18309353
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
Konson A; Ben-Kasus T; Mahajna JA; Danon A; Rimon G; Agbaria R
Cancer Gene Ther; 2004 Dec; 11(12):830-40. PubMed ID: 15359292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
